As of Jul 26, 2024, the Pacira BioSciences stock's PE ratio is 13.18. This results from the current EPS of $1.52 and stock price of $20.03.
The PE ratio of Pacira BioSciences has averaged 228.2 over the last ten years. The current PE ratio of 13.18 is 94% below the historical average. Over the past ten years, PCRX's PE ratio was at its highest in the Dec 2015 quarter at 1,535.8, when the stock price was $76.79 and the EPS was $0.05. The lowest value was in the Jun 2021 quarter, when it reached 15.09 with a price of $60.68 and an EPS of $4.02.
Maximum annual increase: 260.91% in 2021
Maximum annual decrease: -66.39% in 2023
Year | PE ratio | Change |
---|---|---|
2023 | 37.08 | -66.39% |
2022 | 110.31 | 74.16% |
2021 | 63.34 | 260.91% |
2020 | 17.55 | N/A |
2019 | N/A | N/A |
2018 | N/A | N/A |
2017 | N/A | N/A |
2016 | N/A | N/A |
2015 | 1,535.8 | N/A |
2014 | N/A | N/A |
PCRX's current P/E ratio is below the 3, 5 and 10-year averages.
Stock name | PE ratio | Market cap |
---|---|---|
PCRX Pacira BioSciences Inc | 13.18 | $932.32M |
DRRX Durect Corp | N/A | $51.84M |
HRTX Heron Therapeutics Inc | N/A | $459.49M |
CPIX Cumberland Pharmaceuticals Inc | N/A | $20.86M |
CARA Cara Therapeutics Inc | N/A | $20.36M |
OMER Omeros Corp | N/A | $302.47M |
The price to earnings ratio for PCRX stock is 13.18 as of Jul 26, 2024.
The 3-year average PE ratio for PCRX stock is 84.81.
The 5-year average PE ratio for PCRX stock is 114.17.
The highest quarterly PE ratio in the last ten years has been 1,535.8 and it was in the Dec 2015 quarter.
PCRX's price to earnings ratio is currently 94% below its 10-year historical average.
The PE ratio is calculated by taking the latest stock price and dividing it by the EPS for the last 12 months. As of today (Jul 26, 2024), Pacira BioSciences's stock price is $20.03. The earnings per share for the trailing twelve months (TTM) ending Mar 2024 is $1.52. Therefore, Pacira BioSciences's P/E ratio for today is 13.18. PE RATIO(13.18) = STOCK PRICE($20.03) / TTM EPS($1.52)
All PE ratio stats are based on quarterly TTM periods, unless otherwise specified.